- AG9601
Trial Status
Completed
Cancer Type
Stomach Cancer
Protocol Title
A phase II feasibility study of pre-operative and post- operative chemotherapy using epirubicin, cisplatin and protracted venous infusion fluorouracil (ECF) in patients with advanced but operable gastric cancer.
Purpose of the Study
Surgery is the standard treatment for cancers of the stomach (gastric) and lower oesophagus (gullet) that can be removed with an operation, but the cancer often comes back (recurs) despite the best surgery. This trial will determine if adding chemotherapy two months before and two months after surgery improves recurrence and cure rates.
Principal Investigators
Prof Michael Findlay
Dr David Storey
Funding
Pharmacia Pty Limited (Australia)
NHMRC Clinical Trials Centre (Australia)
DETAILED INFORMATION AVAILABLE
Available online at the Australian New Zealand Clinical Trial Registry (ANZCTR) here
Trial Status
Completed
Cancer Type
Stomach Cancer
Publication Reference
Findlay M, Storey D, Gebski V, Hargreaves C, Cullingford G, Boyer M, Trotter J, Archer S, Davidson A, Johnston P, Yuen J, Dhillon H, Della-Fiorentina S, Richardson G, Truskett P, Goldstein D; on behalf of the AGITG. A pilot study of preoperative and postoperative chemotherapy in patients with operable gastric cancer: Australasian Gastrointestinal Trials Group Study 9601. Australian and New Zealand Journal of Surgery 2007; 77(4): 247–252.
Conference Presentation Reference
Cullingford G, Findlay M, Storey D, Boyer M, Trotter J, Archer S, Davidson A, Johnston P, Gebski V, Dhillon H. A phase II feasibility study of preoperative and postoperative chemotherapy (epirubicin, cisplatin and 4FU) in patients with advanced but operable gastric cancer. American Society of Clinical Oncology Annual Scientific Meeting; 18–21 May 2002; Orlando.
Aim
Surgery is the standard treatment for cancers of the stomach (gastric) and lower oesophagus (gullet) that can be removed with an operation, but the cancer often comes back (recurs) despite the best surgery. This trial will determine if adding chemotherapy two months before and two months after surgery improves recurrence and cure rates.
Principal Investigator
Professor Michael Findlay, Medical Oncologist, Auckland Hospital, NZ
Dr David Storey, Upper GI Surgeon, Royal Prince Alfred Hospital, NSW
Funding
Pharmacia Pty Limited (Australia)
NHMRC Clinical Trials Centre (Australia)